HUE029912T2 - Treatments using an ammonia binding agent - Google Patents

Treatments using an ammonia binding agent Download PDF

Info

Publication number
HUE029912T2
HUE029912T2 HUE09739263A HUE09739263A HUE029912T2 HU E029912 T2 HUE029912 T2 HU E029912T2 HU E09739263 A HUE09739263 A HU E09739263A HU E09739263 A HUE09739263 A HU E09739263A HU E029912 T2 HUE029912 T2 HU E029912T2
Authority
HU
Hungary
Prior art keywords
hpn
pba
pagn
patient
ammonia
Prior art date
Application number
HUE09739263A
Other languages
English (en)
Hungarian (hu)
Inventor
Bruce Scharschmidt
Original Assignee
Horizon Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc
Publication of HUE029912T2 publication Critical patent/HUE029912T2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE09739263A 2008-08-29 2009-01-07 Treatments using an ammonia binding agent HUE029912T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9323408P 2008-08-29 2008-08-29

Publications (1)

Publication Number Publication Date
HUE029912T2 true HUE029912T2 (en) 2017-03-28

Family

ID=45604478

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE09739263A HUE029912T2 (en) 2008-08-29 2009-01-07 Treatments using an ammonia binding agent
HUE16176456A HUE040503T2 (hu) 2008-08-29 2009-01-07 Kezelési eljárások ammónia-leválasztó gyógyszerek használatával

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16176456A HUE040503T2 (hu) 2008-08-29 2009-01-07 Kezelési eljárások ammónia-leválasztó gyógyszerek használatával

Country Status (10)

Country Link
JP (3) JP5577341B2 (lt)
DK (1) DK3133396T3 (lt)
ES (2) ES2593378T3 (lt)
HR (2) HRP20161222T1 (lt)
HU (2) HUE029912T2 (lt)
LT (2) LT3133396T (lt)
PL (1) PL2330892T3 (lt)
PT (2) PT3133396T (lt)
SI (1) SI3133396T1 (lt)
TR (1) TR201816616T4 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140094517A (ko) 2011-09-30 2014-07-30 하이페리온 쎄라퓨틱스, 인크. 질소 스캐빈징 약물들의 치료학적 모니터링 방법들
CN104540507A (zh) * 2012-04-20 2015-04-22 海波龙治疗公司 苯乙酸前药的治疗性监测方法
JP2016506378A (ja) * 2012-11-21 2016-03-03 ハイペリオン セラピューティクス,インコーポレイテッド 肝性脳症の治療のための窒素除去薬の投与方法および評価方法
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US20220044801A1 (en) * 2018-10-04 2022-02-10 Atonarp Inc. Living body information acquisition system, health management server, and system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
ES2157422T3 (es) * 1995-02-07 2001-08-16 Brusilow Entpr Llc Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate

Also Published As

Publication number Publication date
PT2330892T (pt) 2016-09-05
PL2330892T3 (pl) 2017-05-31
LT2330892T (lt) 2016-11-25
SI3133396T1 (sl) 2018-12-31
DK3133396T3 (en) 2018-12-03
HUE040503T2 (hu) 2019-03-28
JP2012501329A (ja) 2012-01-19
ES2695534T3 (es) 2019-01-08
JP5577341B2 (ja) 2014-08-20
HRP20161222T1 (hr) 2017-02-10
TR201816616T4 (tr) 2018-11-21
PT3133396T (pt) 2018-12-07
HRP20181877T1 (hr) 2019-01-11
LT3133396T (lt) 2018-11-26
JP2014102255A (ja) 2014-06-05
ES2593378T3 (es) 2016-12-09
JP2012501451A (ja) 2012-01-19

Similar Documents

Publication Publication Date Title
DK2330892T3 (en) METHODS OF TREATMENT WITH USE OF AMMONIAK COLLECTIVE MEDICINES
US20120022157A1 (en) Dosing and monitoring patients on nitrogen-scavenging drugs
US10183006B2 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs
Faggiano et al. Nephrolithiasis in Cushing’s disease: prevalence, etiopathogenesis, and modification after disease cure
Mokhtarani et al. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders
US20180015058A1 (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
HUE029912T2 (en) Treatments using an ammonia binding agent
Young Jr et al. l‐Thyroxine contamination of pharmaceutical d‐thyroxine: probable cause of therapeutic effect
EP2986325B1 (en) Methods of treating urea cycle disorders
Anderson et al. A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers
TW202339759A (zh) PPARẟ促效劑於治療疾病之用途